Diabetes, Vol 45, Issue 2 216-222, Copyright © 1996 by American Diabetes Association

ARTICLES

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients

M Velussi, E Brocco, F Frigato, M Zolli, B Muollo, M Maioli, A Carraro, G Tonolo, P Fresu, AM Cernigoi, P Fioretto and R Nosadini
Centro Antidiabetico di Monfalcone, Gorizia, Italy.

Contrasting information has been reported concerning the course of renal function in NIDDM with hypertension alone or in association with renal damage. The aim of the present study was to elucidate the course of the glomerular filtration rate (GFR) in hypertensive NIDDM patients during antihypertensive therapy. Furthermore, we compared the effects of ACE inhibitors (cilazapril, Inibace, Roche, Milan, Italy) and Ca(2+)-channel blockers (amlodipine, Norvasc, Pfizer, Rome, Italy). Of the hypertensive NIDDM patients attending the outpatient's clinic of the internal medicine departments of the University of Padova and Sassari, 44 participated in the present study. Of these patients, 26 were normoalbuminuric and 18 microalbuminuric. They were randomly treated with either cilazapril or amlodipine. The target of antihypertensive treatment was a value < 140 mmHg for systolic and 85 mmHg for diastolic blood pressure (BP). Microalbuminuria was defined as an albumin excretion rate (AER) between 20 and 200 micrograms/min. GFR was measured by plasma clearance of 51Cr-labeled EDTA at baseline and every 6-12 months during a 3-year follow-up interval. A significant decrease was observed in the values of GFR, AER, and systolic and diastolic BP in normoalbuminuric and microalbuminuric patients during antihypertensive therapy. The GFR fall in the overall population of NIDDM patients was significantly and inversely related to the decrease of mean BP (diastolic + 1/3 pulse pressure) (r = -0.80, P < 0.0001) but not to that of HbA1c, triglycerides, and BMI. The GFR decline (mean +/- SE) per year in the normoalbuminuric patient was 2.03 +/- 0.66 ml.min-1 x 1.73 m-2 (95% CI 0.92-3.17) during cilazapril and 2.01 +/- 0.71 ml.min-1 x 1.73 m-2 (95% CI 0.82-3.11) during amlodipine therapy. The GFR decline per year in the microalbuminuric patient was 2.15 +/- 0.69 ml.min-1 x 1.73 m-2 (95% CI 0.86-3.89) during cilazapril and 2.33 +/- 0.83 ml.min-1 x 1.73 m-2 per year (95% CI 1.03-3.67) during amlodipine therapy. Cilazapril and amlodipine lowered AER to a similar extent in normoalbuminuric and microalbuminuric patients. No significant changes were observed concerning other clinical and biochemical features between the two antihypertensive therapies and particularly HbA1c, BMI, triglycerides, and cholesterol plasma values. These results support the tenet that arterial hypertension plays a pivotal role in contributing to renal damage in NIDDM, even when AER is normal. However, the degree of BP control, with both cilazapril and amlodipine, can successfully delay the slope of GFR decline in hypertensive NIDDM patients with or without incipient nephropathy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. F.M. Strippoli, M. Craig, F. P. Schena, and J. C. Craig Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3081 - 3091. [Abstract] [Full Text] [PDF]

				G. Yasuda, D. Ando, N. Hirawa, S. Umemura, and O. Tochikubo Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy Diabetes Care, August 1, 2005; 28(8): 1862 - 1868. [Abstract] [Full Text] [PDF]

				M. J. Krimholtz, J. Karalliedde, S. Thomas, R. Bilous, and G. Viberti Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S42 - S47. [Abstract] [Full Text] [PDF]

				S. Vijan and R. A. Hayward Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Ann Intern Med, April 1, 2003; 138(7): 593 - 602. [Abstract] [Full Text] [PDF]

				R. Nosadini and G. Tonolo Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus: The Role of Calcium Channel Blockers J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S216 - 223. [Abstract] [Full Text]

				G. Viberti, N. M. Wheeldon, and for the MicroAlbuminuria Reduction With VALsartan Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure-Independent Effect Circulation, August 6, 2002; 106(6): 672 - 678. [Abstract] [Full Text] [PDF]

				C. Arauz-Pacheco, M. A. Parrott, and P. Raskin The Treatment of Hypertension in Adult Patients With Diabetes Diabetes Care, January 1, 2002; 25(1): 134 - 147. [Full Text] [PDF]

				B. Nielsen and A. Flyvbjerg Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview Nephrol. Dial. Transplant., May 1, 2000; 15(5): 581 - 585. [Full Text] [PDF]

				E. Ritz and S. R. Orth Nephropathy in Patients with Type 2 Diabetes Mellitus N. Engl. J. Med., October 7, 1999; 341(15): 1127 - 1133. [Full Text] [PDF]

				M. Rahman and M. C. Smith Chronic Renal Insufficiency: A Diagnostic and Therapeutic Approach Arch Intern Med, September 14, 1998; 158(16): 1743 - 1752. [Abstract] [Full Text] [PDF]